Searchable abstracts of presentations at key conferences in endocrinology

ea0014p558 | (1) | ECE2007

Cabergoline treatment in Cushing’s disease: effect on hypertension, glucose intolerance and dyslipidemia.

Pivonello Rosario , Martino Maria Cristina De , Faggiano Antongiulio , Leo Monica De , Lombardi Gaetano , Hofland Leo J , Lamberts Steven WJ , Colao Annamaria

Cabergoline has been recently demonstrated to normalize cortisol secretion in more than one third of patients with Cushing’s disease (CD). The aim of this study was to evaluate short-term (3-months) and long-term (12-24 months) effects of cabergoline treatment on the main systemic complications of CD, including hypertension, glucose intolerance and dyslipidemia. Twenty patients with CD unsuccessfully treated by neurosurgery entered the study. Cabergoline was admistered at...

ea0056gp34 | Adrenal cortex | ECE2018

Effects of replication of the physiological and non-physiological cortisol rhythm on insulin sensitivity in muscle: a molecular in vitro analysis on synchronized muscular cells

Negri Mariarosaria , Di Gennaro Gilda , Pivonello Claudia , Simeoli Chiara , Vennery Mary Anna , Barbagallo Federica , Iacuaniello Davide , De Martino Maria Cristina , Isidoro Andrea Maria , Colao Annamaria , Pivonello Rosario

Adrenal insufficiency is a rare endocrine disorder characterized by low levels of cortisol associated with increased mortality, also due to inadequate replacement therapy. The replacement with the thrice-daily immediate release hydrocortisone (IRH), in contrast to the once-daily modified-release hydrocortisone (MRH), more appropriately mimicking the physiological circadian rhythm of cortisol (PCRC), is associated with metabolic disorders, mainly due to the non-physiological pe...

ea0093oc51 | Oral communication 8: Interdisciplinary Endocrinology and Environment, Society and Governance | EYES2023

Identifying and characterizing novel HSP90 inhibitors with senolytic activity in a hormone-induced breast cancer-senescence model

Cis Luca , Atlante Sandra , De Martino Sara , Cencioni Chiara , Aiello Aurora , Pirolli Davide , Malavolta Marco , Nanni Simona , De Rosa Maria Cristina , Gaetano Carlo , Farsetti Antonella

Background: Cell senescence is characterized by halted cell proliferation and the acquisition of a pro-inflammatory profile. Cancer cells can enter into senescent state following treatments that inflict DNA damage. Intriguingly, these cells can evade the senescent state, gaining enhanced proliferative capabilities and resistance to further treatment, thereby prompting tumor recurrence. Senolytics offer the potential to eradicate selectively senescent cells, preventing tumor re...

ea0081ep356 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

A unique family with early-onset, severe obesity and hypopituitarism harboring different POMC pathogenic mutations.

Le Collen Lauriane , Delemer Brigitte , Poitou-Bernert Christine , Martine Vaxillaire , Michel Petit Jean , Alexandru Saveanu , Karine Clement , Philippe Froguel , Amelie Bonnefond

Objective: We describe two first cousins presenting with neonatal corticotropic deficiency and severe, early-onset obesity. This study aims to identify the molecular etiology of these disorders in both cases and highlights the limits of genetic investigations.Methods: We collected the clinical-biological data of the family and, more particularly, of the two first cousins (A and B). We performed several constitutive Next-generation Sequencing (NGS) protoc...

ea0063p201 | Diabetes, Obesity and Metabolism 1 | ECE2019

Acquired generalized lipodystrophy: a new cause of Anti-PD-1 immune-related diabetes

Anceau Christine Cugnet , Jehl Alexandre , Vigouroux Corinne , Dalle Stephane , Harou Olivier , Marchand Lucien , Lascols Olivier , Caussy Cyrielle , Thivolet Charles , Laville Martine , Disse Emmanuel

Context: Anti-programmed cell death-1 (Anti-PD-1) antibodies have revolutionized advanced cancer therapy. Anti-PD1 therapy is responsible for immune-related adverse events, with frequent endocrine manifestations. Acquired generalized lipodystrophy (AGL), is a rare disease, thought to be immune-mediated, characterized by loss of adipose tissue and insulin resistance-associated complications. We describe the first case of AGL induced by immune checkpoint therapy.<p class="ab...

ea0070aep682 | Pituitary and Neuroendocrinology | ECE2020

Perception of stature and quality of life in young adult men referred for tall stature during adolescence. Perception of stature and quality of life in young adult men referred for tall stature during adolescence.

De Schepper Jean , Wynand Justine , De Waele Kathleen , Van der Straaten Saskia , Cools Martine , Den Brinker Marieke , Dotrement Hilde , Vanbesien Jesse , Gies Inge

Background and aims: Little is known about the long-term psychosocial effect of tallness and its treatment in male adolescents.1 Therefore, psychosocial outcome, including adult coping with tall stature were investigated in young adult men, who had consulted for tall stature during adolescence.Methods: All adult men (age >18 years) who had been referred for tall stature or rapid growth during adolescence (ages 11 to 16 years) between 2010 ...

ea0056p859 | Pituitary - Clinical | ECE2018

PROMPT: a prospective study to assess efficacy and safety of metyrapone in endogenous Cushing’s syndrome

Nieman Lynnette , Akinci Baris , Beckers Albert , Bolanowski Marek , Hanzu Felicia Alexandra , Mezosi Emese , Tonjes Anke , Bostnavaron Martine , Jaspart Amelie , Borensztein Pascale , Boscaro Marco , Scaroni Carla

Introduction: Metyrapone blocks cortisol production by inhibiting 11ß-hydroxylation of 11-deoxycortisol, the last step of cortisol synthesis. Based on observational retrospective studies published over more than 50 years metyrapone is approved for the treatment of endogenous Cushing’s syndrome (CS) in 14 European countries. PROMPT is the first prospective study to document the safety and efficacy of metyrapone using modern assay techniques.Desi...

ea0071002 | Novel model of sex steroid deficiency in mice to study the physiological effects of delayed and suppressed puberty | BES2020

Novel model of sex steroid deficiency in mice to study the physiological effects of delayed and suppressed puberty

Kim Na Ri , Rougin Khalil , Karel David , Leen Antonio , Dieter Schollaert , Ludo Deboel , HerckErik Van , Nele Wardenier , Martine Cools , Brigitte Decallonne , Frank Claessens , Vanessa Dubois , Dirk Vanderschueren

Background: Sex steroids are critical for skeletal development and maturation during puberty as well as skeletal maintenance during adult life. However, the exact time during puberty when sex steroids have the highest impact as well as the ability of bone to recover from transient sex steroid deficiency is unclear. The latter is highly relevant in the clinical context of delayed puberty, since the impact of a delayed pubertal onset on adult bone health remains elusive. Surgica...

ea0042oc4 | (1) | Androgens2016

The use of apolipoprotein D as a biomarker for androgen sensitivity identifies a new type of androgen insensitivity syndrome that is not associated with a mutation in the androgen receptor gene

Hornig Nadine C , Ukat Martine , Schweikert Hans-Udo , Hiort Olaf , Werner Ralf , Drop Stenvert LS , Cools Martine , Hughes Ieuan A , Audi Laura , Ahmed S Faisal , Demiri Jeta , Rodens Pascal , Worch Lisa , Wehner Gaby , Kulle Alexandra E , Dunstheimer Desiree , Muller-Roszberg Elke , Reinehr Thomas , Hadidi Ahmed T , Eckstein Anne K , van der Horst Christof , Seif Christoph , Siebert Reiner , Ammerpohl Ole , Holterhus Paul-Martin

Although androgen insensitivity syndrome (AIS) is commonly suspected as a cause of a 46,XY disorder of sex development (DSD), only about half of these cases can be attributed to an inactivating mutation within the coding sequence (CDS) of the androgen receptor (AR) gene. This led to the hypothesis that disrupted AR activation in AIS may also be caused by a defect in a co-factor of AR-activity. However, so far mutations in AR co-factors leading to AIS have not been ide...

ea0041ep883 | Pituitary - Clinical | ECE2016

Disease activity and lifestyle influence the occurrence of cardiovascular risk factors and cardiovascular events in acromegaly

Sardella Chiara , Cappellani Daniele , Urbani Claudio , Manetti Luca , Marconcini Giulia , Tomisti Luca , Lupi Isabella , Rossi Giuseppe , Scattina Ilaria , Lombardi Martina , Di Bello Vitantonio , Marcocci Claudio , Martino Enio , Bogazzi Fausto

Context: Acromegalic patients have a high-risk cardiovascular profile. However, the determinants of cardiovascular risk factors and major cardiovascular events (MACE), which may develop after diagnosis of acromegaly, are not fully understood.Objectives: To identify the predictors for systemic comorbidities and MACE, after diagnosis of disease. The role of therapy for acromegaly on the occurrence of such complications was also evaluated.<p class="abst...